Is Rubicon Research Ltd (RUBICON) a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Rubicon Research Ltd is a average quality company .

Is Rubicon Research Ltd (RUBICON) undervalued or overvalued?

The key valuation ratios of Rubicon Research Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is Rubicon Research Ltd (RUBICON) share price return in the past 10 years?

Data is not available for this company

Is Rubicon Research Ltd (RUBICON) a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Rubicon Research Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

What is the share price of Rubicon Research Ltd (RUBICON)?

Company share prices are keep on changing according to the market conditions. The current trading price of Rubicon Research Ltd (RUBICON) on 13-Apr-2026 16:59:59 at 16:59 is 819.60.

What is the market cap of Rubicon Research Ltd (RUBICON)?

Market capitalization is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 13-Apr-2026 at 16:59, the market cap of Rubicon Research stood at Rs. 13530.95 Cr.

What is the P/E ratio of Rubicon Research?

The latest standalone P/E ratio of Rubicon Research as of 13-Apr-2026 is 80.76.

What is the P/B ratio of Rubicon Research Ltd (RUBICON)?

The latest standalone P/B ratio of Rubicon Research Ltd (RUBICON) as of 13-Apr-2026 is 10.46.

What is the 52-week high and low of Rubicon Research Ltd (RUBICON)?

The 52-week high of Rubicon Research Ltd (RUBICON) is Rs. 887.95 and the 52-week low is Rs. 571.00.

What is the TTM revenue of Rubicon Research Ltd (RUBICON)?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Rubicon Research is Rs. 1073.84 (Cr.).

Rubicon Research Ltd (RUBICON) Share Analysis – Quality, Valuation Zone & Price Trend & DeciZen Rating

Name: Rubicon Research Ltd (RUBICON)
Brand: Rubicon Research

10 Year X-Ray :

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	7.4%	3%	1.6%	14.4%	28.2%	21.2%	4.7%	5.5%	7.9%	26.7%	-
Value Creation Index ⓘ	-0.5	-0.8	-0.9	0.1	1.1	0.6	-0.7	-0.6	-0.4	0.9	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	39.2	48.9	65.2	154	263	331	400	407	631	1,074	1,074
Sales YoY Gr.	-	24.8%	33.4%	136%	71%	26%	20.7%	1.9%	54.7%	70.3%	-
Adj EPS ⓘ	0.2	0.1	0.1	1.3	3.3	3.2	1.1	-0.3	0.9	10.5	10.2
YoY Gr.	-	-40%	-22.2%	1757.1%	154.6%	-3.9%	-65.4%	-123.6%	NA	1105.8%	-
BVPS (₹) ⓘ	4.8	12.9	12.7	14.3	22.8	26.3	27.4	28.2	29.7	41.6	78.3
Adj Net Profit ⓘ	0.9	1.2	0.9	18.4	50.4	48.3	16.8	-4	13.2	162	168
Cash Flow from Ops. ⓘ	7.6	-4.3	-15.4	-10.7	9.3	46.9	-37.1	-79	83.2	29.7	-
Debt/CF from Ops. ⓘ	3.8	-6.4	-1.9	-4.7	3.3	2	-4.6	-4	4.8	13.3	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	44.5%	32.5%	39%	70.3%
Adj EPS ⓘ	60.3%	26%	112.1%	1105.8%
BVPSⓘ	27.2%	12.8%	15%	40%
Share Price	-	-	-	-

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	1.9	1.1	0.5	9.7	18.1	12.6	4	-0.9	2.9	28.3	16.9
Op. Profit Mgn % ⓘ	25.1	17.8	8.2	23.2	34.1	33.6	10	10.2	11.6	25.2	24.1
Net Profit Mgn % ⓘ	2.3	2.5	1.4	12	19.2	14.6	4.2	-1	2.1	15.1	15.6
Debt to Equity ⓘ	0.6	0.2	0.2	0.3	0.1	0.2	0.4	0.7	0.9	0.6	-
Working Cap Days ⓘ	342	330	365	272	256	274	324	457	371	288	71
Cash Conv. Cycle ⓘ	131	151	178	122	139	164	176	264	194	134	28

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 16.90%

Sales growth is growing at healthy rate in last 3 years 38.98%

Net Profit is growing at healthy rate in last 3 years 112.06%

Debt to equity has declined versus last 3 years average to 0.61

Sales growth is good in last 4 quarters at 13.80%

No data to display

	Standalone	Consolidated
TTM EPS (₹)	10.2	8.1
TTM Sales (₹ Cr.)	1,074	1,284
BVPS (₹) ⓘ	78.3	73.9
Reserves (₹ Cr.) ⓘ	1,277	1,203
P/BV ⓘ	10.46	11.10
PE ⓘ	80.76	100.70

From the Market
52 Week Low / High (₹)	571.00 / 887.95
All Time Low / High (₹)	571.00 / 887.95
Market Cap (₹ Cr.)	13,531
Equity (₹ Cr.)	16.5
Face Value (₹)	1
Industry PE ⓘ	58.8

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	39	49	65	154	263	331	400	407	631	1,074
Operating Expenses ⓘ +	29	40	60	119	173	220	360	366	557	804
Manufacturing Costs	3	3	4	7	26	63	110	93	79	109
Material Costs	5	9	14	35	45	55	103	125	214	308
Employee Cost	12	14	22	28	34	41	59	74	85	128
Other Costs ⓘ	10	14	20	49	68	61	88	74	179	259
Operating Profit ⓘ	10	9	5	35	90	111	40	41	73	270
Operating Profit Margin (%)	25.1%	17.7%	8.2%	22.8%	34.1%	33.6%	10.0%	10.2%	11.6%	25.1%
Other Income ⓘ +	0	1	4	6	18	11	17	28	26	20
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Interest ⓘ	3	3	2	3	6	9	9	19	31	34
Depreciation ⓘ	5	5	6	8	18	28	32	33	35	32
Profit Before Tax ⓘ	3	1	1	31	84	85	17	18	34	223
Tax ⓘ	2	0	0	9	25	32	0	6	10	56
Profit After Tax	1	1	1	22	59	53	17	13	24	168
PAT Margin (%)	2.3%	2.5%	1.5%	14.2%	22.5%	16.0%	4.2%	3.1%	3.9%	15.6%
Adjusted EPS (₹)	0.2	0.1	0.1	1.6	3.9	3.5	1.1	0.8	1.6	10.9
Dividend Payout Ratio (%)	0%	0%	0%	0%	2%	1%	5%	2%	0%	0%

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	48	181	179	201	347	399	416	429	452	642
Share Capital ⓘ	21	5	5	5	5	5	5	5	15	15
Reserves ⓘ	27	177	174	196	342	394	411	424	437	626
Debt +	24	23	26	42	24	82	155	293	357	355
Long Term Debt	9	12	12	28	4	38	63	97	93	64
Short Term Debt	15	11	14	14	19	43	91	196	264	290
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	4	4	10	19	22	32	58	74	98	184
Others Liabilities ⓘ	15	14	15	38	48	57	49	72	109	159
Total Liabilities ⓘ	92	223	230	300	442	570	678	868	1,016	1,339
Fixed Assets
Net Fixed Assets ⓘ +	37	41	44	68	151	177	181	183	232	259
Gross Block	65	75	82	111	211	265	299	334	410	461
Accumulated Depreciation	28	34	38	43	60	88	119	152	178	202
CWIP ⓘ	15	16	25	57	2	4	3	25	10	6
Investments ⓘ	0	115	78	18	35	32	19	26	34	36
Inventories	2	7	14	19	38	57	58	99	181	258
Trade Receivables	19	24	37	84	140	154	234	350	252	501
Cash Equivalents	1	2	2	9	33	79	44	46	48	37
Others Assets ⓘ	18	18	30	45	42	67	142	139	259	241
Total Assets ⓘ	92	223	230	300	442	570	678	868	1,016	1,339

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	8	-4	-15	-11	9	47	-37	-79	83	30
PBT ⓘ	3	1	1	31	84	85	17	18	34	223
Adjustment ⓘ	6	5	10	16	20	26	25	40	52	68
Changes in Working Capital ⓘ	1	-10	-26	-57	-68	-31	-71	-136	13	-235
Tax Paid ⓘ	-2	-1	-0	-0	-27	-33	-8	-0	-16	-27
Cash Flow From Investing Activity ⓘ +	-8	-122	17	1	-85	-32	-86	-34	-130	-10
Capex	-8	-7	-23	-64	0	0	0	-37	-56	-70
Net Investments	0	0	-3	-4	-14	3	0	0	-11	-4
Others ⓘ	-0	-114	42	70	-72	-35	-86	3	-63	64
Cash Flow From Financing Activity ⓘ +	-0	127	-3	16	76	52	65	124	46	-34
Net Proceeds from Shares ⓘ	0	147	0	0	0	0	0	0	0	8
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	28	0	44	10	-30
Interest Paid ⓘ	-3	-3	-2	-2	-6	-1	0	-18	-28	-33
Dividend Paid ⓘ	0	0	0	0	0	0	-1	-0	-0	-0
Others ⓘ	2	-17	-1	19	82	25	66	98	64	21
Net Cash Flow ⓘ	-1	1	-1	6	-0	67	-58	11	-1	-14

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	3.16	1.15	0.53	11.48	21.55	14.19	4.09	3.01	5.53	30.64
ROCE (%)	7.44	3.02	1.62	14.43	28.21	21.21	4.71	5.45	7.91	26.65
Asset Turnover Ratio	0.45	0.31	0.29	0.58	0.71	0.66	0.64	0.53	0.67	0.91
PAT to CFO Conversion(x)	8	-4	-15	-0.5	0.15	0.89	-2.18	-6.08	3.46	0.18
Working Capital Days
Receivable Days	166	162	172	144	156	162	177	262	174	128
Inventory Days	14	35	60	40	40	52	52	70	81	75
Payable Days	248	168	190	154	168	180	160	194	147	167

About Rubicon Research Ltd

Rubicon Research was incorporated on May 6, 1999, as a private limited company under the Companies Act, 1956, under the name ‘Rubicon Consultants Private Limited’, pursuant to a certificate of incorporation issued by the RoC.

Rubicon Research is a pharmaceutical formulations company, driven by innovation through focused research and development, with an increasing portfolio of specialty products and drug-device combination products targeting regulated markets and in particular the United States. Based on the peer set (of seven listed Indian companies assessed by F&S, and the company), it is the only Indian pharmaceutical player with a complete focus on regulated markets.

The company’s multi-disciplinary, data-driven, and return on investment (ROI) centric product selection framework is geared towards identifying sustainable opportunities for new product development. It identifies and pursues such opportunities in a manner that provides it a competitive advantage by leveraging its development, manufacturing, and commercialization capabilities to create and grow its share of the market.

Business area of the company

Rubicon Research, incorporated in 1999, is an integrated pharmaceutical company with business encompassing the entire value chain in the research, development and production of pharmaceutical products. Further, the company has robust sales and distribution capabilities in the US.

Products of the company

Metoprolol Tartrate
Cyclobenzaprine Hydrochloride
Carbidopa-Levodopa
Diclofenac Potassium
Baclofen
Rabeprazole Sodium
Lidocaine Hydrochloride
Tramadol Hydrochloride

History and milestones

2007: Received investment from Kotak India Venture Fund - I, Kotak India Venture Limited and Kotak Employees Investment Trust.
2011: Commencement of manufacturing of certain special drugs in Ambernath Manufacturing Facility.
2011: Receipt of certificate of GMP compliance for Ambernath Manufacturing Facility for tablet manufacturing and secondary packaging by Medicines and Healthcare Products Regulatory Agency, United Kingdom.
2013: Receipt of GMP clearance approval for Ambernath Manufacturing Facility from Department of Health and Ageing Therapeutic Goods Administration, Australian Government.
2014: Receipt of approval for its product i.e., ‘metoprolol tartrate tablets’ from the Food & Drug Administration, United State of America.
2016: Acquisition of majority stake by ECP III Pte Ltd.
2017: Receipt of certificate of GMP compliance for Ambernath Manufacturing Facility from the Ministerio De Sandidad, Servicios Sociales E Igualdad, Spain.
2019: Acquisition of majority stake by General Atlantic Singapore RR Pte. Ltd., from ECP III Pte. Ltd.
2019: Acquisition of Impopharma Canada Limited by Rubicon Research Canada Limited
2021: Acquired the business of Meditab Specialities Limited on a slump sale basis.
2022: Set up own sales and marketing front end in US via its Material Subsidiary.
2023: Receipt of certificate of GMP compliance for Satara Manufacturing Facility of non-sterile liquid drug manufacturer and pre-approval coverage provided for non-sterile liquid product by US FDA.
2024: Acquisition of Validus Pharmaceuticals LLC.
2024: ANDA pre-approval drug inspection of nasal spray block at Ambernath Manufacturing Facility by USFDA.
2024: Receipt of supplement approval for Thane R&D Facility as a testing site of drug substance - lead test from USFDA.
2024: Received USFDA establishment inspection report for Ambernath Manufacturing Facility.
2024: Commencement of manufacturing of nasal products at Ambernath Manufacturing Facility.
2025: Received new drug application approval from USFDA for Lopressor (Metoprolol Tartrate) oral solution.
2025: Received USFDA establishment inspection report for Thane R&D Facility.
2025: Acquisition of Pithampur Manufacturing Facility from Alkem Laboratories Limited.
2025: Acquisition of AIM RX 3PL LLC.

Build a Stress-Tested Portfolio.

Our Sapphire Advisory uses the ABC Concept to ensure you never have to panic during a market correction.

Core Stocks

STABILITY

Booster Stocks

GROWTH

Amplifier Stocks

ASYMMETRY

● Conflict-Free ● SEBI Registered ● 15Y+ Track Record

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Rubicon Research Ltd (RUBICON) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Rubicon Research Share Price